Wire · opportunities
VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
VIR-5500, a PSMA-targeted T-cell engager for late-line metastatic castration-resistant prostate cancer, received FDA fast track designation following promising phase 1 results showing high response rates and a manageable safety profile. Phase 3 trials are expected to start in 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 8 Oct 2026 and 9 Oct 2026.
◆ ◆ The Wire takeaway
FDA fast track for VIR-5500 proves regulatory backing for PSMA-targeted therapies in late-stage prostate cancer. You can start lining up trial partnerships and patient recruitment before phase 3 trials kick off next year.
◆ Coverage
3 sources · first reported 8 Oct 2026 · latest 9 Oct 2026
◆ Related on Wire
◆ Topics